Premium
Metformin severely impairs in vivo muscle oxidative capacity in a rat model of type 2 diabetes
Author(s) -
Prompers Jeanine J,
Wessels Bart,
Ciapaite Jolita,
Nicolay Klaas
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.887.14
Subject(s) - metformin , in vivo , medicine , type 2 diabetes , endocrinology , skeletal muscle , diabetes mellitus , oxidative phosphorylation , in vitro , respirometry , chemistry , biology , biochemistry , microbiology and biotechnology
Objective To investigate the effects of metformin on in vivo and in vitro skeletal muscle mitochondrial function in Zucker diabetic fatty (ZDF) rats using 31 P magnetic resonance spectroscopy (MRS) and high‐resolution respirometry (HRR), respectively. Methods 12‐week old healthy ( fa/+ ) and diabetic ( fa/fa ) ZDF rats were treated with metformin (0, 30, 100 or 300 mg/kg body weight/day) for 15 days by oral gavage. At day 14, in vivo 31 P MRS was performed on the tibialis anterior (TA) muscle to measure PCr recovery. At day 15, animals were killed and TA muscles were excised for in vitro HRR measurements. Results Metformin treatment decreased PCr recovery rates in a dose‐dependent manner in both healthy fa/+ and diabetic fa/fa rats. Whereas, the clinical dose of 30 mg/kg/day had no significant effect, PCr recovery rates were ~22% and ~47% decreased at 100 and 300 mg/kg/day. HRR measurements showed a similar, but less pronounced effect of metformin on in vitro mitochondrial function. Conclusion Metformin treatment impairs in vivo skeletal muscle oxidative capacity in rats in a dose‐dependent manner. This research was funded by a VIDI grant from the Netherlands Organisation for Scientific Research (NWO).